Meg Jardine's Publications

About Meg Jardine's Publications

Honorary Professorial Fellow, The George Institute for Global Health
  • Associate Professor, Faculty of Medicine, UNSW Sydney

  • Managing the symptom burden associated with maintenance dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

    Kidney International Date published:

  • Cystatin C-based estimated glomerular filtration rate and risk of stroke in the general population: a prospective cohort study

    Clinical Kidney Journal Date published:

  • Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial

    Cardiovascular Diabetology Date published:

  • Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials

    Journal of the American Heart Association Date published:

  • Safety and Effectiveness of Rivaroxaban Versus Warfarin Across GFR Levels in Atrial Fibrillation: A Population-Based Study in Australia and Canada

    Kidney Medicine Date published:

  • Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial

    American Journal of Kidney Diseases Date published:

  • Estimating the population-level kidney benefits of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease in Australian primary care

    Unknown Date published:

  • The prevalence of chronic kidney disease in Australian primary care: analysis of a national general practice dataset

    Unknown Date published:

  • A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

    Nature Medicine Date published:

  • Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering

    BMJ Open Diabetes Research & Care Date published:

  • The impact of dexmedetomidine on postoperative delirium: should we throw out a DECADE of research?

    British Journal of Anaesthesia Date published:

  • The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials

    Diabetes, Obesity and Metabolism Date published:

  • Sex and Gender in Randomized Controlled Trials of Adults Receiving Maintenance Dialysis: A Meta-epidemiologic Study

    American Journal of Kidney Diseases Date published:

  • Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

    The Lancet Date published:

  • Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR

    Clinical Journal of the American Society of Nephrology Date published:

  • WCN23-1085 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATY- THE ALIGN STUDY

    Kidney International Reports Date published: